About


Slide sansero-life-sciences-about-title-7 A Winning Formula

Slide sansero-life-sciences-about-title-7 A Winning Formula

The Sansero Life Sciences team has over 30 years of research and clinical experience in plant biotechnology, tissue culture and genetics and over 15 years experience developing proprietary and stable plant genetics.

Our science team is recognized by federal regulation bodies for extensive work in CDSA-controlled substances, has developed dozens of proprietary cannabis genetics over the past 9 years and is at the forefront of these groundbreaking new industries in medical healthcare leveraging state-of-the-art research facilities in Alberta.

Our proprietary formulations are ready and set for clinical trials, it is our goal to become a global leader in the legal cultivation, research, development and ultimate commercialization of psilocybin and related products.

The Sansero Life Sciences team has over 30 years of research and clinical experience in plant biotechnology, tissue culture and genetics and over 15 years experience developing proprietary and stable plant genetics.

Our science team has developed dozens of proprietary cannabis genetics over the past 9 years and is at the forefront of these groundbreaking new industries in medical healthcare leveraging state-of-the-art research facilities in Alberta.

Our proprietary formulations are ready and set for clinical trials, it is our goal to become a global leader in the legal cultivation, research, development and ultimate commercialization of psilocybin and related products.


The Sansero Life Sciences team has over 30 years of research and clinical experience in plant biotechnology, tissue culture and genetics and over 15 years experience developing proprietary and stable plant genetics.

Our science team has developed dozens of proprietary cannabis genetics over the past 9 years and is at the forefront of these groundbreaking new industries in medical healthcare leveraging state-of-the-art research facilities in Alberta.

Our proprietary formulations are ready and set for clinical trials, it is our goal to become a global leader in the legal cultivation, research, development and ultimate commercialization of psilocybin and related products.





Our Team



Our Team



Our Team


STEVE SADOFF
Chief Executive Officer

  • 13+ experiences developing, launching & growing brands and products within highly regulated environments
  • Leadership positions within Cannabis, Beverage Alcohol (Bacardi, AB InBev), Pharmaceutical (Novartis) and Natural Health (Jamieson Laboratories) organizations
  • Chief Operating Officer of SheCann Cannabis Inc. leading business development and financial strategy
  • Expert in Natural Health Product Development and Commercialization

DARRYL HUDSON, PhD
Chief Science Officer


  • PhD, Plant Molecular Biology and Genetics
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx where he led the development of dozens of proprietary cannabis varietals with registered Breeder’s rights
  • 2+ years developing and testing psilocybin formulations pursuant to Jamaican regulations
  • Expert in controlled substances SOPs and QA standards

IGOR KOVALCHUK, MD, PhD
Laboratory Principal

  • 20+ years experience in plant biotechnology, genetics and breeding
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx
  • Over 150 peer reviewed publications and 10 patents in the areas of epigenetics, epigenomics, bioinformatics, genetic engineering, plant biotechnology and next generation sequencing
  • Research focus on medicinal plants including opium poppy and cannabis

DANIEL GAUDET, MSc
Master Cultivator & Biologist

  • Masters degree in analytical chemistry with a focus on immunoassay development
  • Research expertise in plant breeding, molecular genetics, tissue culture, analytical chemistry, biotechnology and mycology
  • Responsible for developing molecular genotyping methods for screening desirable traits of wheat for the breeding program at Agriculture and Agri-Foods Canada
  • 3+ years experience working in the research laboratory on the University of Lethbridge campus

STEVE SADOFF
Chief Executive Officer


DARRYL HUDSON, PhD
Chief Science Officer


IGOR KOVALCHUK, MD, PhD
Laboratory Principal


DANIEL GAUDET, MSc
Master Cultivator & Biologist



STEVE SADOFF
Chief Executive Officer


DARRYL HUDSON, PhD
Chief Science Officer


IGOR KOVALCHUK, MD, PhD
Laboratory Principal


DANIEL GAUDET, MSc
Master Cultivator & Biologist




  • 13+ experiences developing, launching & growing brands and products within highly regulated environments
  • Leadership positions within Cannabis, Beverage Alcohol (Bacardi, AB InBev), Pharmaceutical (Novartis) and Natural Health (Jamieson Laboratories) organizations
  • Chief Operating Officer of SheCann Cannabis Inc. leading business development and financial strategy
  • Expert in Natural Health Product Development and Commercialization

  • PhD, Plant Molecular Biology and Genetics
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx where he led the development of dozens of proprietary cannabis varietals with registered Breeder’s rights
  • 2+ years developing and testing psilocybin formulations pursuant to Jamaican regulations
  • Expert in controlled substances SOPs and QA standards

  • 20+ years experience in plant biotechnology, genetics and breeding
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx
  • Over 150 peer reviewed publications and 10 patents in the areas of epigenetics, epigenomics, bioinformatics, genetic engineering, plant biotechnology and next generation sequencing
  • Research focus on medicinal plants including opium poppy and cannabis

  • Masters degree in analytical chemistry with a focus on immunoassay development
  • Research expertise in plant breeding, molecular genetics, tissue culture, analytical chemistry, biotechnology and mycology
  • Responsible for developing molecular genotyping methods for screening desirable traits of wheat for the breeding program at Agriculture and Agri-Foods Canada
  • 3+ years experience working in the research laboratory on the University of Lethbridge campus

Track record of leading businesses to commercial success

  • 13+ experiences developing, launching & growing brands and products within highly regulated environments
  • Leadership positions within Cannabis, Beverage Alcohol (Bacardi, AB InBev), Pharmaceutical (Novartis) and Natural Health (Jamieson Laboratories) organizations
  • Chief Operating Officer of SheCann Cannabis Inc. leading business development and financial strategy
  • Expert in Natural Health Product Development and Commercialization

Extensive Scientific Expertise & Innovation


  • PhD, Plant Molecular Biology and Genetics
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx where he led the development of dozens of proprietary cannabis varietals with registered Breeder’s rights
  • 2+ years developing and testing psilocybin formulations pursuant to Jamaican regulations
  • Expert in controlled substances SOPs and QA standards

Professor and Board of Governors Research Chair, University of Lethbridge

  • 20+ years experience in plant biotechnology, genetics and breeding
  • Co-Founder and officer of InPlanta Biotechnology Inc. and Pathways Rx
  • Over 150 peer reviewed publications and 10 patents in the areas of epigenetics, epigenomics, bioinformatics, genetic engineering, plant biotechnology and next generation sequencing
  • Research focus on medicinal plants including opium poppy and cannabis

Laboratory Research & Mycology Expertise

  • Masters degree in analytical chemistry with a focus on immunoassay development
  • Research expertise in plant breeding, molecular genetics, tissue culture, analytical chemistry, biotechnology and mycology
  • Responsible for developing molecular genotyping methods for screening desirable traits of wheat for the breeding program at Agriculture and Agri-Foods Canada
  • 3+ years experience working in the research laboratory on the University of Lethbridge campus

Advisors



Advisors



Advisors


DAVID WOOD, PhD
Legal Counsel / IP & Regulatory Advisor


IRIE SELKIRK
Business Development & Patient Care Advisor

MICHAEL SALIKEN
Legal Counsel / Corporate Secretary

DAVID WOOD, PhD
Legal Counsel / IP & Regulatory Advisor


IRIE SELKIRK
Business Development & Patient Care Advisor

MICHAEL SALIKEN
Legal Counsel / Corporate Secretary


  • Partner and patent agent at Borden Ladner Gervais LLP, Canada’s largest law firm
  • Practice focuses on the cannabis and entheogenic industries
  • Advised multiple federal cannabis licensees
  • Experienced in assessing patentable products/technology, the patent application process, and patent litigation
  • PhD in Biochemistry aiding his experiences with chemical, biochemical, information, and mechanical technologies and, medical device industries

  • Advisor on patient acquisition and care to Licensed Producers, clinics and retailers including Canopy Growth, Hiku Brands, WeedMD, Emblem, Grow Wise and Fire & Flower
  • Extensive experience as an educator and liaison to health care professionals (Doctors and Registered Nurses) in the cannabis industry
  • Recognized international speaker on plant & natural medicine policy, regulation, tourism and marketing
  • Founder of the world’s first legal psilocybin microdose retreat, Rise Wellness Retreat, in Jamaica

  • Partner in the business group at Borden Ladner Gervais LLP, Canada’s largest law firm
  • 10+ years experience providing business advisory, corporate governance and legal services to companies in the cannabis, entheogen, technology and energy industries
  • Co-founder and board member of LaSanta Botanicals Ltd – a Columbian-based cannabis pharmaceuticals company
  • Corporate Secretary of National Access Cannabis Corp. (TSXV: META), Canada’s largest cannabis retail company

  • Partner and patent agent at Borden Ladner Gervais LLP, Canada’s largest law firm
  • Practice focuses on the cannabis and entheogenic industries
  • Advised multiple federal cannabis licensees
  • Experienced in assessing patentable products/technology, the patent application process, and patent litigation
  • PhD in Biochemistry aiding his experiences with chemical, biochemical, information, and mechanical technologies and, medical device industries

  • Advisor on patient acquisition and care to Licensed Producers, clinics and retailers including Canopy Growth, Hiku Brands, WeedMD, Emblem, Grow Wise and Fire & Flower
  • Extensive experience as an educator and liaison to health care professionals (Doctors and Registered Nurses) in the cannabis industry
  • Recognized international speaker on plant & natural medicine policy, regulation, tourism and marketing
  • Founder of the world’s first legal psilocybin microdose retreat, Rise Wellness Retreat, in Jamaica

  • Partner in the business group at Borden Ladner Gervais LLP, Canada’s largest law firm
  • 10+ years experience providing business advisory, corporate governance and legal services to companies in the cannabis, entheogen, technology and energy industries
  • Co-founder and board member of LaSanta Botanicals Ltd – a Columbian-based cannabis pharmaceuticals company
  • Corporate Secretary of National Access Cannabis Corp. (TSXV: META), Canada’s largest cannabis retail company

DAVID WOOD, PhD
Legal Counsel / IP & Regulatory Advisor

  • Partner and patent agent at Borden Ladner Gervais LLP, Canada’s largest law firm
  • Practice focuses on the cannabis and entheogenic industries
  • Advised multiple federal cannabis licensees
  • Experienced in assessing patentable products/technology, the patent application process, and patent litigation
  • PhD in Biochemistry aiding his experiences with chemical, biochemical, information, and mechanical technologies and, medical device industries

IRIE SELKIRK
Business Development & Patient Care Advisor

  • Advisor on patient acquisition and care to Licensed Producers, clinics and retailers including Canopy Growth, Hiku Brands, WeedMD, Emblem, Grow Wise and Fire & Flower
  • Extensive experience as an educator and liaison to health care professionals (Doctors and Registered Nurses) in the cannabis industry
  • Recognized international speaker on plant & natural medicine policy, regulation, tourism and marketing
  • Founder of the world’s first legal psilocybin microdose retreat, Rise Wellness Retreat, in Jamaica

MICHAEL SALIKEN
Legal Counsel / Corporate Secretary

  • Partner in the business group at Borden Ladner Gervais LLP, Canada’s largest law firm
  • 10+ years experience providing business advisory, corporate governance and legal services to companies in the cannabis, entheogen, technology and energy industries
  • Co-founder and board member of LaSanta Botanicals Ltd – a Columbian-based cannabis pharmaceuticals company
  • Corporate Secretary of National Access Cannabis Corp. (TSXV: META), Canada’s largest cannabis retail company



SABRINA RAMKELLAWAN
Clinical Trials Advisor


SHAWN RIPLEY
Business Advisor

ELIZABETH M. NIELSON, PhD, CASAC
Advisor

SABRINA RAMKELLAWAN
Clinical Trials Advisor


SHAWN RIPLEY
Business Advisor

ELIZABETH M. NIELSON, PhD, CASAC
Advisor


  • 10+ years of managing research and operations in highly regulated environments including Pharmaceutical companies (Apotex Inc. and Biovail) and global research organizations
  • Held Senior positions in the cannabis industry including a licensed producer (TerrAscend Corp) and a cannabis clinic (Apollo Applied Research) as well as consulting for several licensed producers
  • 15 years of conducting phase I-IV clinical trials including cannabinoid products, vaccines, devices, biologics, and many innovative, novel, and generic drugs
  • Conducted & consulted on cannabis research for MedReleaf, Canntab, Bedrocan, Tilray, Canntrust, TerrAscend, Apollo Applied Research, and an independent cannabis device company

  • Key contributions to founding and growth of the lab revenues to over $100mm per year at Canada’s largest commercial laboratory
  • Appointed by City council to serve three terms on Calgary’s most senior advisory board charged with approving major policy
  • Recognized by Health Canada as a qualified Quality Assurance Person under the MMPR and ACMPR cannabis regulations
  • Founded EFX to provide non smokable predictable dosage formats of cannabis for medical patients in Canada

  • Psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders
  • Unmatched psychedelic clinical study experience – Therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder (NYU), MDMA-assisted treatment PTSD (MAPS), and psilocybin-assisted treatment of treatment resistant depression (Compass Pathways)
  • Co-founder of Fluence, providing continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings
  • 10+ years of managing research and operations in highly regulated environments including Pharmaceutical companies (Apotex Inc. and Biovail) and global research organizations
  • Held Senior positions in the cannabis industry including a licensed producer (TerrAscend Corp) and a cannabis clinic (Apollo Applied Research) as well as consulting for several licensed producers
  • 15 years of conducting phase I-IV clinical trials including cannabinoid products, vaccines, devices, biologics, and many innovative, novel, and generic drugs
  • Conducted & consulted on cannabis research for MedReleaf, Canntab, Bedrocan, Tilray, Canntrust, TerrAscend, Apollo Applied Research, and an independent cannabis device company
  • Key contributions to founding and growth of the lab revenues to over $100mm per year at Canada’s largest commercial laboratory
  • Appointed by City council to serve three terms on Calgary’s most senior advisory board charged with approving major policy
  • Recognized by Health Canada as a qualified Quality Assurance Person under the MMPR and ACMPR cannabis regulations
  • Founded EFX to provide non smokable predictable dosage formats of cannabis for medical patients in Canada

  • Psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders
  • Unmatched psychedelic clinical study experience – Therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder (NYU), MDMA-assisted treatment PTSD (MAPS), and psilocybin-assisted treatment of treatment resistant depression (Compass Pathways)
  • Co-founder of Fluence, providing continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings

SABRINA RAMKELLAWAN
Clinical Trials Advisor

  • 10+ years of managing research and operations in highly regulated environments including Pharmaceutical companies (Apotex Inc. and Biovail) and global research organizations
  • Held Senior positions in the cannabis industry including a licensed producer (TerrAscend Corp) and a cannabis clinic (Apollo Applied Research) as well as consulting for several licensed producers
  • 15 years of conducting phase I-IV clinical trials including cannabinoid products, vaccines, devices, biologics, and many innovative, novel, and generic drugs
  • Conducted & consulted on cannabis research for MedReleaf, Canntab, Bedrocan, Tilray, Canntrust, TerrAscend, Apollo Applied Research, and an independent cannabis device company

SHAWN RIPLEY
Business Advisor

  • Key contributions to founding and growth of the lab revenues to over $100mm per year at Canada’s largest commercial laboratory
  • Appointed by City council to serve three terms on Calgary’s most senior advisory board charged with approving major policy
  • Recognized by Health Canada as a qualified Quality Assurance Person under the MMPR and ACMPR cannabis regulations
  • Founded EFX to provide non smokable predictable dosage formats of cannabis for medical patients in Canada

ELIZABETH M. NIELSON, PhD, CASAC
Advisor

  • Psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders
  • Unmatched psychedelic clinical study experience – Therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder (NYU), MDMA-assisted treatment PTSD (MAPS), and psilocybin-assisted treatment of treatment resistant depression (Compass Pathways)
  • Co-founder of Fluence, providing continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings